Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)

Prior treatment

• Known previous heparin induced thrombocytopenia – HIT

Other illness

• Current use of antiplatelet therapy or disease with indication for antiplatelet therapy not yet initiated.
• Known hypersensitivity to clopidogrel or dalteparin
• Current use of full dose anti-coagulation or disease with indication of full dose anti-coagulation. Patients already on primary prophylaxis can be included.
• Known allergies to study medication.
• Active bleeding or severe risk of bleeding.
• Clinically significant liver disease (e.g., chronic active hepatitis, or cirrhosis).

Lab values

• Platelets <30×10^9/L.

Other

• Known CYP2C19 genotype that influences clopidogrel metabolism (genotyping not necessary)
• Severe intestinal malabsorption.
• Known pregnancy (pregnancy test is not necessary)

• Participants are >18 years of age.
• Patients with locally advanced, metastatic or recurrent (after intended therapeutic treatment) pancreatic ductal adenocarcinoma.
• Patients where there is planned treatment or already receive treatment for their pancreatic ductal cancer.
• Patients receiving neoadjuvant chemotherapy before intended curative surgery.